Efficacy and safety of injectable dulaglutide 1.5 mg among type 2 diabetes patients in clinics at king saud medical city, riyadh, saudi arabia

HIGHLIGHTS

• What: The aim of this study was to assess the efficacy of weekly 1.5 mg dulaglutide on improving glycemic control and reducing body weight independently after 6 and 12 months from baseline. Because there have been few studies examining this topic in Saudi Arabia, the rationale for conducting this research is to evaluate the efficacy and safety of dulaglutide among Saudi patients with T2DM. The study demonstrates similar results in HbA1c reduction and slightly higher weight reduction, with a mean reduction of HbA1c by 1.12 after 6 months and 1.43% after 12 months and . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.